*Department of Urology
†German Cancer Consortium (DKTK)
‡Department of Medical Oncology, West German Cancer Center, University Hospital Essen
§Institute of Pathology, University Hospital Essen, Essen
∥Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
C.K. reports consulting fees Apogepha, research funding Advanced Accelerator Applications (Novartis). B.A.H. reports personal fees from ABX, Bayer, LightPoint Medical Inc., Janssen R&D, Bristol-Myers-Squibb and Astellas; research funding from Profound Medical, German Cancer Aid, German Research Foundation, Janssen R&D, Bristol-Myers-Squibb, MSD, Pfizer and Astellas; and travel fees from AstraZeneca, Janssen R&D and Astellas. V.G. reports fees from Astellas, AstraZeneca, BMS, EISAI, Ipsen, Janssen-Cilag, Merck Serono, MSD, Novartis, Pfizer, Roche, and research grants from BMS, Ipsen, MSD and Pfizer. The remaining authors have no funding or conflicts of interest to disclose.
Reprints: Christopher Darr, MD, Department of Urology, University Hospital Essen, Hufelandstr. 55, 45147 Essen (e-mail: [email protected]).
